Demographic, clinical characteristics and comorbidities*
| Number of patients | 2225 |
| Age at first assessment | 49.6 (14.3) |
| 18–34 | 378 (17.0%) |
| 35–54 | 979 (44.0%) |
| 55–79 | 855 (38.5%) |
| 80+ | 11 (0.5%) |
| Age at onset of symptoms | 24.2 (19.1) |
| <12 | 715 (36.2%) |
| 12–18 | 184 (9.3%) |
| >18 | 1076 (54.5%) |
| Gender | |
| Female | 1389 (62.4%) |
| Male | 836 (37.6%) |
| Ethnicity | |
| Caucasian | 1744 (79.1%) |
| Non-Caucasian | 462 (20.9%) |
| BMI (kg/m2) | 30.8 (7.1) |
| Smoking status | |
| Never smoker | 1490 (68.3%) |
| Ex-smoker | 617 (28.3%) |
| Current smoker | 76 (3.5%) |
| Atopic disease | 1378 (62.8%) |
| Spinal bone density (T-Score) | −0.7 (1.4) |
| Femoral neck bone density (T-Score) | −0.4 (1.1) |
| FEV1 (% predicted) | 65.3 (21.3) |
| FVC (% predicted) | 83.1 (19.7) |
| FEV1/FVC | 63.4 (17.3) |
| Residual volume (% predicted) | 132.0 (44.1) |
| Total lung capacity (% predicted) | 103.9 (18.7) |
| ACQ6 Score | 2.9 (1.4) |
| Exacerbations requiring rescue steroids in last year | 4 (2, 7) |
| Exacerbations requiring hospital admission in last year | 0 (0, 1) |
| Invasive ventilation (ever) | 193 (10.0%) |
| Eczema | 63 (2.9%) |
| Nasal polyps | 356 (16.4%) |
| Gastro-oesophageal reflux | 367 (16.9%) |
| Depression or anxiety | 180 (8.3%) |
*Mean (SD), median (IQR) or count (%) as appropriate.
ACQ, Asthma Control Questionnaire; BMI, body mass index.